NBIX - Neurocrine Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

79.40

+1.22 (+1.56%)

At close: 4:00PM EDT

Stock chart is not supported by your current browser

Previous Close	78.18
Open	78.00
Bid	76.45 x 100
Ask	90.00 x 100
Day's Range	77.01 - 80.42
52 Week Range	41.76 - 92.98
Volume	523,000
Avg. Volume	843,190

Market Cap	7.137B
Beta	2.08
PE Ratio (TTM)	N/A
EPS (TTM)	-1.62
Earnings Date	May 7, 2018 - May 11, 2018
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	1995-12-29
1y Target Est	105.36

Trade prices are not sourced from all markets

All

News

Press Releases

PR Newswire3 days ago
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Neurocrine Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK , April 19, 2018 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty ...
PR Newswire3 days ago
Neurocrine Biosciences to Present New Data from INGREZZA® at the 2018 American Academy of Neurology Annual Meeting
SAN DIEGO, April 18, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX) today announced that new data for once-daily INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), will be presented at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles, Calif., April 21-27, 2018. Highlighted presentations include analysis of the short- and long-term effects of INGREZZA on TD symptoms by body region, long-term INGREZZA safety and efficacy data from the KINECT 4 Phase III open-label study and data from RE-KINECT, a real-world screening study of patients with possible TD. "The symptoms of tardive dyskinesia are heterogeneous, with each patient experiencing tardive dyskinesia somewhat differently.
Market Realist10 days ago
Ingrezza: Boosting Neurocrine’s Top Line
Neurocrine Biosciences (NBIX) is a pharmaceutical company with a focus on neurological and endocrine-based diseases and disorders. Its leading product on the market is Ingrezza, a vesicular monoamine transporter 2 (or VMAT2) inhibitor used in the treatment of movement disorders. Ingrezza was approved by the FDA for the treatment of tardive dyskinesia (or TD) in April 2017.
Reuters12 days ago
FDA needs more time to review AbbVie, Neurocrine's uterine pain drug
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said.
Reuters12 days ago
FDA extends review for AbbVie, Neurocrine's uterine pain drug
AbbVie Inc and Neurocrine Biosciences Inc said on Tuesday the U.S. Food and Drug Administration notified the companies that it requires more time to review the marketing application for their uterine pain drug. The agency requested more time to review additional information regarding the results of liver function tests provided by AbbVie in connection with the application for Elagolix in endometriosis-associated pain, the companies said. The FDA is now expected to make its decision in the third quarter of 2018, three months later than initially expected.
PR Newswire12 days ago
AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain
- FDA requires extended time for review of additional information in New Drug Application (NDA) - Elagolix clinical trial program largest prospective randomized endometriosis trial conducted to date - ...
Forbes12 days ago
A Sixth Sense For Biotech Has Made Joe Edelman A Hedge Fund Star
Who's the world's best hedge fund manager? David Tepper? Stevie Cohen? Try Joe Edelman, a wannabe psychologist with a bead on biotech who has quietly built the best track record of the past two decades.
Markit12 days ago
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Markit17 days ago
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
Motley Fool25 days ago
3 Biotechs That Could Get Big Boosts in April
April showers might bring May flowers. But they also bring major FDA decisions for these biotechs.
Market Realist27 days ago
How Is Teva Progressing with Its Specialty Assets Portfolio?
Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers. The company’s specialty products portfolio is made up of Copaxone, Austedo, Fremanezumab, and a number of other assets that are in clinical trials, one of which is Fasinumab.
Simply Wall St.last month
Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX) Expected To Breakeven
Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The US$7.85B market-cap company announcedRead More...
Motley Foollast month
Is This AbbVie's Next Blockbuster Drug?
Another positive phase 3 trial may position endometriosis-pain treatment candidate elagolix as a future billion-dollar seller.
Markitlast month
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc NASDAQ/NGS:NBIX
PR Newswire2 months ago
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences
SAN DIEGO , March 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Kevin Gorman , CEO of Neurocrine Biosciences, will present at the following investor conferences: ...
MarketWatch2 months ago
AbbVie, Neurocrine shares rise after positive results for uterine fibroids drug
AbbVie Inc. and Neurocrine Biosciences Inc. shares rose 1.7% and 1.1% respectively in premarket trade Wednesday after the companies announced that their drug met its primary endpoint in a phase 3 trial ...
PR Newswire2 months ago
AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
− First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints − Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual ...
Investopedia2 months ago
5 Stocks to Outperform in 2018’s Volatile Market
TipRanks, which ranks analysts' recommendations, has picked a handful of stocks as safe bets.
Zacks Small Cap Research2 months ago
NBIX: Will File an NDA for Opicapone in 1H19
On Feb. 14, 2018, Neurocrine Biosciences, Inc. (NBIX) announced the company will file a new drug application (NDA) for opicapone in the first half of 2019 following receipt of the meeting minutes from the January 2018 meeting with the FDA. During that meeting, the FDA did not request that Neurocrine conduct an additional Phase 3 study for opicapone prior to filing the NDA. Opicapone is a peripherally-acting and highly selective inhibitor of catechol-o-methyltransferase (COMT) to be used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors in patients with Parkinson’s disease (PD).
Markit2 months ago
See what the IHS Markit Score report has to say about Neurocrine Biosciences Inc.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
PR Newswire2 months ago
Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
SAN DIEGO, Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided guidance on the regulatory path forward to support the New Drug Application (NDA) for opicapone, an investigational drug for Parkinson's disease, after receiving meeting minutes from the January 2018 meeting with the FDA. Most importantly, the Neurology Division of the FDA has not requested that Neurocrine conduct an additional Phase III study for opicapone prior to the NDA filing.
Thomson Reuters StreetEvents2 months ago
Edited Transcript of NBIX earnings conference call or presentation 13-Feb-18 10:00pm GMT
Q4 2017 Neurocrine Biosciences Inc Earnings Call
Associated Press2 months ago
Neurocrine misses 4Q profit forecasts
The San Diego-based company said it had profit of 7 cents per share. The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings ...
PR Newswire2 months ago
Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch ...
ACCESSWIRE2 months ago
Neurocrine Biosciences, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) will be discussing their earnings results in their Q4 Earnings Call to be held on February 13, 2018, at 5:00 ...